Trials / Not Yet Recruiting
Not Yet RecruitingNCT07491367
Pilot Exploration of Platelet Characterization of Platelet Rich Plasma Created by Two Different Systems
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- University of California, San Francisco · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators would like to study the differences in the quality of Platelet Rich Plasma (PRP) between two different machines in those with knee osteoarthritis. Knee osteoarthritis means your cartilage has been worn down, and it affects your knee joint. Both machines, the APEX Biologix XCELL PRP System and the Emcyte PurePRP Supraphysiologic Concentrating System, are FDA approved, commercially available, and makes PRP. The investigators will check if the platelets in the PRP have different amounts or work differently. The investigators will also assess participants symptoms after the injection and compare the two different preparation systems.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Platelet Rich Plasma | The Platelet Rich Plasma (PRP) participants will receive in this study will be made by Emcyte PurePRP Supraphysiologic Concentrating System or the APEX Biologix XCELL PRP System. |
| DEVICE | Emcyte PurePRP Supraphysiologic Concentrating System | Platelet Rich Plasma (PRP) will be made by the Emcyte PurePRP Supraphysiologic Concentrating System. |
| DEVICE | APEX Biologix XCELL PRP System | Platelet Rich Plasma (PRP) will be made by APEX Biologix XCELL PRP System. |
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2028-03-01
- Completion
- 2028-09-01
- First posted
- 2026-03-24
- Last updated
- 2026-03-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT07491367. Inclusion in this directory is not an endorsement.